Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 280

1.

Comprehensive Metabolomic Search for Biomarkers to Differentiate Early Stage Hepatocellular Carcinoma from Cirrhosis.

Kim DJ, Cho EJ, Yu KS, Jang IJ, Yoon JH, Park T, Cho JY.

Cancers (Basel). 2019 Oct 6;11(10). pii: E1497. doi: 10.3390/cancers11101497.

2.

Pharmacokinetic Interaction Among Telmisartan, Amlodipine, and Hydrochlorothiazide After a Single Oral Administration in Healthy Male Subjects.

Moon SJ, Jeon JY, Yu KS, Kim MG.

Clin Ther. 2019 Sep 26. pii: S0149-2918(19)30424-2. doi: 10.1016/j.clinthera.2019.08.020. [Epub ahead of print]

PMID:
31564513
3.

NaCl Nanoparticles as a Cancer Therapeutic.

Jiang W, Yin L, Chen H, Paschall AV, Zhang L, Fu W, Zhang W, Todd T, Yu KS, Zhou S, Zhen Z, Butler M, Yao L, Zhang F, Shen Y, Li Z, Yin A, Yin H, Wang X, Avci FY, Yu X, Xie J.

Adv Mater. 2019 Sep 25:e1904058. doi: 10.1002/adma.201904058. [Epub ahead of print]

PMID:
31553099
4.

Pharmacokinetics of high-dose carboplatin in children undergoing high-dose chemotherapy and autologous stem cell transplantation with BSA-based dosing.

Hong CR, Kang HJ, Moon SJ, Oh J, Hong KT, Choi JY, Yu KS, Shin HY.

Bone Marrow Transplant. 2019 Aug 28. doi: 10.1038/s41409-019-0655-5. [Epub ahead of print]

PMID:
31462686
5.

Pharmacokinetic interactions between telmisartan/amlodipine and rosuvastatin after multiple oral administrations in healthy Korean male subjects.

Moon SJ, Jeon JY, Jang K, Yu KS, Lim Y, Kim MG.

Drug Des Devel Ther. 2019 Jul 25;13:2533-2542. doi: 10.2147/DDDT.S210364. eCollection 2019.

6.

Pharmacokinetics and tolerability of IDP-73152 mesylate after a single oral administration under fasted and fed conditions in healthy volunteers.

Shin D, Park SI, Lee HS, An KM, Jung J, Lee M, Yu KS.

Drug Des Devel Ther. 2019 Jul 24;13:2483-2490. doi: 10.2147/DDDT.S209238. eCollection 2019.

7.

Factors influencing insulin sensitivity during hyperinsulinemic-euglycemic clamp in healthy Korean male subjects.

Shin D, Eom YS, Chon S, Kim BJ, Yu KS, Lee DH.

Diabetes Metab Syndr Obes. 2019 Apr 10;12:469-476. doi: 10.2147/DMSO.S195350. eCollection 2019.

8.

Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.

Lee J, Yoon SH, Yi S, Kim AH, Kim B, Lee S, Yu KS, Jang IJ, Cho JY.

Drug Metab Pharmacokinet. 2019 Aug;34(4):247-252. doi: 10.1016/j.dmpk.2019.04.002. Epub 2019 Apr 17.

PMID:
31088714
9.

URC102, a potent and selective inhibitor of hURAT1, reduced serum uric acid in healthy volunteers.

Lee HA, Yu KS, Park SI, Yoon S, Onohara M, Ahn Y, Lee H.

Rheumatology (Oxford). 2019 May 5. pii: kez140. doi: 10.1093/rheumatology/kez140. [Epub ahead of print]

PMID:
31056705
10.

Development of a Korean-specific virtual population for physiologically based pharmacokinetic modelling and simulation.

Kim Y, Hatley O, Rhee SJ, Yi S, Lee HA, Yoon S, Chung JY, Yu KS, Lee H.

Biopharm Drug Dispos. 2019 Apr;40(3-4):135-150. doi: 10.1002/bdd.2178.

PMID:
30921829
11.

Population Pharmacokinetic Study of Prophylactic Fluconazole in Preterm Infants for Prevention of Invasive Candidiasis.

Kim YK, Lee J, Oh J, Rhee SJ, Shin SH, Yoon SH, Lee S, Kim HS, Yu KS.

Antimicrob Agents Chemother. 2019 May 24;63(6). pii: e01960-18. doi: 10.1128/AAC.01960-18. Print 2019 Jun.

PMID:
30910892
12.

Pharmacokinetics of Ursodeoxycholic Acid in Elderly Volunteers Compared With Younger Adults in a Korean Population.

Lee S, Yoon S, Chung H, Ji SC, Yoon SH, Yu KS, Cho JY, Chung JY.

J Clin Pharmacol. 2019 Aug;59(8):1085-1092. doi: 10.1002/jcph.1409. Epub 2019 Mar 18.

PMID:
30882914
13.

Ursodeoxycholic acid exerts hepatoprotective effects by regulating amino acid, flavonoid, and fatty acid metabolic pathways.

Kim DJ, Chung H, Ji SC, Lee S, Yu KS, Jang IJ, Cho JY.

Metabolomics. 2019 Feb 27;15(3):30. doi: 10.1007/s11306-019-1494-5.

PMID:
30830474
14.

Adventitial Stromal Cells Define Group 2 Innate Lymphoid Cell Tissue Niches.

Dahlgren MW, Jones SW, Cautivo KM, Dubinin A, Ortiz-Carpena JF, Farhat S, Yu KS, Lee K, Wang C, Molofsky AV, Tward AD, Krummel MF, Peng T, Molofsky AB.

Immunity. 2019 Mar 19;50(3):707-722.e6. doi: 10.1016/j.immuni.2019.02.002. Epub 2019 Feb 26.

PMID:
30824323
15.

Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients.

Park ES, Lee AR, Kim DH, Lee JH, Yoo JJ, Ahn SH, Sim H, Park S, Kang HS, Won J, Ha YN, Shin GC, Kwon SY, Park YK, Choi BS, Lee YB, Jeong N, An Y, Ju YS, Yu SJ, Chae HB, Yu KS, Kim YJ, Yoon JH, Zoulim F, Kim KH.

J Hepatol. 2019 Jun;70(6):1093-1102. doi: 10.1016/j.jhep.2019.02.006. Epub 2019 Feb 20.

PMID:
30794889
16.

A Personalized CYP2C19 Phenotype-Guided Dosing Regimen of Voriconazole Using a Population Pharmacokinetic Analysis.

Kim Y, Rhee SJ, Park WB, Yu KS, Jang IJ, Lee S.

J Clin Med. 2019 Feb 10;8(2). pii: E227. doi: 10.3390/jcm8020227.

17.

A physiologically-based pharmacokinetic model adequately predicted the human pharmacokinetic profiles of YH4808, a novel K+-competitive acid blocker.

Lee HA, Lee KR, Jang SB, Chung SY, Yu KS, Lee H.

Eur J Pharm Sci. 2019 Mar 15;130:1-10. doi: 10.1016/j.ejps.2019.01.009. Epub 2019 Jan 11.

PMID:
30641142
18.

AICAR, an AMPK activator, protects against cisplatin-induced acute kidney injury through the JAK/STAT/SOCS pathway.

Tsogbadrakh B, Ryu H, Ju KD, Lee J, Yun S, Yu KS, Kim HJ, Ahn C, Oh KH.

Biochem Biophys Res Commun. 2019 Feb 12;509(3):680-686. doi: 10.1016/j.bbrc.2018.12.159. Epub 2019 Jan 4.

PMID:
30616891
19.

Assessment of Hepatic Cytochrome P450 3A Activity Using Metabolic Markers in Patients with Renal Impairment.

Kim AH, Yoon S, Lee Y, Lee J, Bae E, Lee H, Kim DK, Lee S, Yu KS, Jang IJ, Cho JY.

J Korean Med Sci. 2018 Oct 31;33(53):e298. doi: 10.3346/jkms.2018.33.e298. eCollection 2018 Dec 31.

20.

Pharmacokinetic comparison of gemigliptin 50 mg and metformin 500 mg as a fixed-dose combination and loose combination
.

Lee SW, Park SI, Lee S, Chung JY, Yu KS.

Int J Clin Pharmacol Ther. 2019 Feb;57(2):117-124. doi: 10.5414/CP203289.

PMID:
30574864
21.

Quantification of Thiopurine Nucleotides in Erythrocytes and Clinical Application to Pediatric Acute Lymphoblastic Leukemia.

Moon SY, Lim JH, Kim EH, Nam Y, Yu KS, Hong KT, Choi JY, Hong CR, Kim H, Kang HJ, Shin HY, Lee K, Song J, Lee SY, Song SH.

Ther Drug Monit. 2019 Feb;41(1):75-85. doi: 10.1097/FTD.0000000000000575.

22.

The Use of Post-ablation Stimulated Thyroglobulin in Predicting Clinical Outcomes in Differentiated Thyroid Carcinoma - What Cut-off Values Should We Use?

Wong KCW, Ng TY, Yu KS, Kwok JSS, Chan KCA, Suen JJS, Leung SF, Chan ATC.

Clin Oncol (R Coll Radiol). 2019 Feb;31(2):e11-e20. doi: 10.1016/j.clon.2018.10.009. Epub 2018 Nov 17.

PMID:
30454940
23.

Physiologically Based Pharmacokinetic Modeling of Fimasartan, Amlodipine, and Hydrochlorothiazide for the Investigation of Drug-Drug Interaction Potentials.

Rhee SJ, Lee HA, Lee S, Kim E, Jeon I, Song IS, Yu KS.

Pharm Res. 2018 Oct 15;35(12):236. doi: 10.1007/s11095-018-2511-5.

PMID:
30324316
24.

Utility of Integrated Analysis of Pharmacogenomics and Pharmacometabolomics in Early Phase Clinical Trial: A Case Study of a New Molecular Entity.

Oh J, Yi S, Gu N, Shin D, Yu KS, Yoon SH, Cho JY, Jang IJ.

Genomics Inform. 2018 Sep;16(3):52-58. doi: 10.5808/GI.2018.16.3.52. Epub 2018 Sep 30.

25.

Pharmacokinetic Characteristics and Limited Sampling Strategies for Therapeutic Drug Monitoring of Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections.

Kim EJ, Oh J, Lee K, Yu KS, Chung JY, Hwang JH, Nam EY, Kim HS, Kim M, Park JS, Song KH, Kim ES, Song J, Kim HB.

Ther Drug Monit. 2019 Feb;41(1):102-106. doi: 10.1097/FTD.0000000000000572.

PMID:
30299430
26.

Physicochemical properties and oxidative stability of frying oils during repeated frying of potato chips.

Yu KS, Cho H, Hwang KT.

Food Sci Biotechnol. 2017 Dec 12;27(3):651-659. doi: 10.1007/s10068-017-0292-y. eCollection 2018 Jun.

27.

Lack of a Clinically Significant Pharmacokinetic Interaction Between Pregabalin and Thioctic Acid in Healthy Volunteers.

Rhee SJ, Lee H, Ahn LY, Lim KS, Yu KS.

Clin Ther. 2018 Oct;40(10):1720-1728.e2. doi: 10.1016/j.clinthera.2018.08.016. Epub 2018 Sep 18.

PMID:
30241687
28.

HL156A, a novel pharmacological agent with potent adenosine-monophosphate-activated protein kinase (AMPK) activator activity ameliorates renal fibrosis in a rat unilateral ureteral obstruction model.

Tsogbadrakh B, Ju KD, Lee J, Han M, Koh J, Yu Y, Lee H, Yu KS, Oh YK, Kim HJ, Ahn C, Oh KH.

PLoS One. 2018 Aug 30;13(8):e0201692. doi: 10.1371/journal.pone.0201692. eCollection 2018.

29.

Ursodeoxycholic acid improves liver function via phenylalanine/tyrosine pathway and microbiome remodelling in patients with liver dysfunction.

Kim DJ, Yoon S, Ji SC, Yang J, Kim YK, Lee S, Yu KS, Jang IJ, Chung JY, Cho JY.

Sci Rep. 2018 Aug 8;8(1):11874. doi: 10.1038/s41598-018-30349-1.

30.

Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers.

Choi Y, Lee S, Jang IJ, Yu KS.

Drug Des Devel Ther. 2018 Jul 24;12:2301-2309. doi: 10.2147/DDDT.S165171. eCollection 2018.

31.

Favorable Outcome of Post-Transplantation Cyclophosphamide Haploidentical Peripheral Blood Stem Cell Transplantation with Targeted Busulfan-Based Myeloablative Conditioning Using Intensive Pharmacokinetic Monitoring in Pediatric Patients.

Hong KT, Kang HJ, Choi JY, Hong CR, Cheon JE, Park JD, Park KD, Song SH, Yu KS, Jang IJ, Shin HY.

Biol Blood Marrow Transplant. 2018 Nov;24(11):2239-2244. doi: 10.1016/j.bbmt.2018.06.034. Epub 2018 Jul 6.

PMID:
29981849
32.

Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic.

Sunwoo J, Kim YK, Choi Y, Yu KS, Nam H, Cho YL, Yoon S, Chung JY.

Drug Des Devel Ther. 2018 Jun 11;12:1707-1714. doi: 10.2147/DDDT.S155657. eCollection 2018.

33.

Pharmacokinetics of fludarabine and its association with clinical outcomes in paediatric haematopoietic stem cell transplantation patients.

Chung H, Hong KT, Lee JW, Rhee SJ, Kim S, Yoon SH, Yu KS, Kang HJ.

Bone Marrow Transplant. 2019 Feb;54(2):284-292. doi: 10.1038/s41409-018-0260-z. Epub 2018 Jun 18.

PMID:
29915216
34.

Effect of food on the pharmacokinetics of YH4808, a potassium-competitive acid blocker, after single- and multiple-oral dosing in healthy subjects.

Kim E, Kim A, Yi S, Kim YK, Jang SB, Byun HM, Yoon SH, Cho JY, Jang IJ, Yu KS, Lee S.

Eur J Clin Pharmacol. 2018 Oct;74(10):1261-1272. doi: 10.1007/s00228-018-2502-9. Epub 2018 Jun 15.

PMID:
29907887
35.

Safety, tolerability, pharmacodynamics and pharmacokinetics of DWP14012, a novel potassium-competitive acid blocker, in healthy male subjects.

Sunwoo J, Oh J, Moon SJ, Ji SC, Lee SH, Yu KS, Kim HS, Lee A, Jang IJ.

Aliment Pharmacol Ther. 2018 Jul;48(2):206-218. doi: 10.1111/apt.14818. Epub 2018 Jun 4.

PMID:
29863280
36.

Assessment of induced CYP3A activity in pregnant women using 4β-hydroxycholesterol: Cholesterol ratio as an appropriate metabolic marker.

Kim AH, Kim B, Rhee SJ, Lee Y, Park JS, Lee SM, Kim SM, Lee S, Yu KS, Jang IJ, Cho JY.

Drug Metab Pharmacokinet. 2018 Jun;33(3):173-178. doi: 10.1016/j.dmpk.2018.04.004. Epub 2018 Apr 25.

PMID:
29759884
37.

Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese.

Choi Y, Yoon S, Matsumoto K, Ohta Y, Lee S, Yu KS, Jang IJ.

Drug Des Devel Ther. 2018 Apr 30;12:1045-1051. doi: 10.2147/DDDT.S148117. eCollection 2018.

38.

Evaluation of drug interactions between fimasartan and rosuvastatin after single and multiple doses in healthy Caucasians.

Lee J, Rhee SJ, Lee S, Yu KS.

Drug Des Devel Ther. 2018 Apr 6;12:787-794. doi: 10.2147/DDDT.S145339. eCollection 2018.

39.

The Genetic Polymorphism UGT1A4*3 Is Associated with Low Posaconazole Plasma Concentrations in Hematological Malignancy Patients Receiving the Oral Suspension.

Suh HJ, Yoon SH, Yu KS, Cho JY, Park SI, Lee E, Lee JO, Koh Y, Song KH, Choe PG, Kim ES, Bang SM, Kim HB, Kim I, Kim NJ, Song SH, Park WB, Oh MD.

Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e02230-17. doi: 10.1128/AAC.02230-17. Print 2018 Jul.

40.

Extract of Rhus verniciflua stokes protects against renal ischemia-reperfusion injury by enhancing Nrf2-mediated induction of antioxidant enzymes.

Choi DR, Jeong JH, Yu KS, Lee NS, Jeong YG, Kim DK, Na CS, Na DS, Hwang WM, Han SY.

Exp Ther Med. 2018 Apr;15(4):3827-3835. doi: 10.3892/etm.2018.5913. Epub 2018 Feb 28.

41.

Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects.

Kim YK, Shin KH, Alderman J, Yu KS, Jang IJ, Lee S.

Drug Des Devel Ther. 2018 Feb 19;12:331-337. doi: 10.2147/DDDT.S149119. eCollection 2018.

42.

A non-linear pharmacokinetic-pharmacodynamic relationship of metformin in healthy volunteers: An open-label, parallel group, randomized clinical study.

Chung H, Oh J, Yoon SH, Yu KS, Cho JY, Chung JY.

PLoS One. 2018 Jan 17;13(1):e0191258. doi: 10.1371/journal.pone.0191258. eCollection 2018.

43.

Impaired autophagy promotes bile acid-induced hepatic injury and accumulation of ubiquitinated proteins.

Kim S, Han SY, Yu KS, Han D, Ahn HJ, Jo JE, Kim JH, Shin J, Park HW.

Biochem Biophys Res Commun. 2018 Jan 1;495(1):1541-1547. doi: 10.1016/j.bbrc.2017.11.202. Epub 2017 Dec 1.

PMID:
29198703
44.

Early Therapeutic Drug Monitoring of Posaconazole Oral Suspension in Patients With Hematologic Malignancies.

Suh HJ, Kim I, Cho JY, Park SI, Yoon SH, Hwang JH, Bae JY, Lee JO, Koh Y, Song KH, Choe PG, Yu KS, Kim ES, Kim HB, Bang SM, Kim NJ, Song SH, Park WB, Oh MD.

Ther Drug Monit. 2018 Feb;40(1):115-119. doi: 10.1097/FTD.0000000000000469.

PMID:
29189664
46.

A comparative pharmacokinetic and tolerability analysis of the novel orotic acid salt form of tenofovir disoproxil and the fumaric acid salt form in healthy subjects.

Kim YK, Choi MJ, Oh TY, Yu KS, Lee S.

Drug Des Devel Ther. 2017 Nov 6;11:3171-3177. doi: 10.2147/DDDT.S149125. eCollection 2017.

47.

Comparable pharmacokinetics and pharmacodynamics of two epoetin alfa formulations Eporon® and Eprex® following a single subcutaneous administration in healthy male volunteers.

Yoon S, Rhee SJ, Heo SJ, Oh TY, Yoon SH, Cho JY, Lee S, Yu KS.

Drug Des Devel Ther. 2017 Oct 27;11:3127-3135. doi: 10.2147/DDDT.S142673. eCollection 2017.

48.

Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects.

Choi Y, Lee SW, Kim A, Jang K, Nam H, Cho YL, Yu KS, Jang IJ, Chung JY.

J Antimicrob Chemother. 2018 Jan 1;73(1):183-190. doi: 10.1093/jac/dkx367.

PMID:
29069400
49.

Performance of the Minto model for the target-controlled infusion of remifentanil during cardiopulmonary bypass.

Cho YJ, Jo WY, Oh H, Koo CH, Oh J, Cho JY, Yu KS, Jeon Y, Kim TK.

Anaesthesia. 2017 Oct;72(10):1196-1205. doi: 10.1111/anae.14019.

50.

Identification of ω- or (ω-1)-Hydroxylated Medium-Chain Acylcarnitines as Novel Urinary Biomarkers for CYP3A Activity.

Kim B, Lee J, Shin KH, Lee S, Yu KS, Jang IJ, Cho JY.

Clin Pharmacol Ther. 2018 May;103(5):879-887. doi: 10.1002/cpt.856. Epub 2017 Oct 10.

PMID:
28877336

Supplemental Content

Support Center